The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in cutaneous tumors progression and novel strategies of pharmacological inhibition of matrix metalloproteinases;Rola metaloproteaz macierzy i tkankowych inhibitorów metaloproteaz w progresji nowotworów skóry a nowe strategie farmakologicznej inhibicji metaloproteaz macierzy

Przeglad Dermatologiczny

Volumn 91, Issue 2, 2004, Pages 153-160

  Bogaczewicz, Jarosław ^a   Chodorowska, Grazyna ^a   Krasowska, Dorota ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Cutaneous tumors; Matrix metalloproteinases; Matrix metalloproteinases inhibitors; Tissue inhibitors of metalloproteinases; Tumor progression

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; BATIMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE; MM 1270; PRINOMASTAT; REBIMASTAT; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; REVIEW; SKIN TUMOR; TUMOR GROWTH;

EID: 2542477946     PISSN: 00332526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Nagase H., Woessner J.F. Jr: Matrix metalloproteinases. J Biol Chem 1999, 274, 21491-21494.
2. Murphy G., Gavrilovic J.: Proteolysis and cell migration: creating a path? Curr Opin Cell Biol 1999, 11, 614-621.
3. Marchenko G.N., Strongin A.Y.: MMP-28, a new human matrix metalloproteinase with an unusual cysteine switch sequence is widely expressed in tumors. Gene 2001, 265, 87-93.
4. Kleiner D.E., Stetler-Stevenson W.G.: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999, supl. 43, 42-51.
5. Bogaczewicz J., Chodorowska G., Krasowska D.: Rola metaloproteaz macierzy i tkankowych inhibitorów metaloproteaz w twardzinie układowej. Przegl Dermatol 2003, 90, 373-382.
6. Ahonen M., Baker A.H., Kahari V.M.: Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998, 58, 2310-2315.
7. Hofmann U.B., Westphal J.R., Zendman A.J. i inni: Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 2000, 191, 245-256.
8. Airola K., Karonen T., Vaalamo M. i inni: Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999, 80, 733-743.
9. Vaisanen A., Tuominen H., Kallioinen M. inni: Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996, 180, 283-289.
10. Vaisanen A., Kallioinen M., Taskinen P.J. i inni: Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998, 186, 51-58.
11. Van den Oord J.J., Paemen L., Opdenakker G. i inni: Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997, 151, 665-670.
12. Butler G.S., Butler M.J., Atkinson S.J. i inni: The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998, 273, 871-880.
13. Brooks P.C., Stromblad S., Sanders L.C. i inni: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996, 85, 683-693.
14. Benbow U., Schoenermark M.P., Mitchell T.I. i inni: A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen. J Biol Chem 1999, 274, 25371-25378.
15. Gruss C., Herlyn M.: Role of cadherins and matrixins in melanoma. Curr Opin Oncol 2001, 13, 117-123.
16. Kanekura T., Chen X., Kanzaki T.: Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 2002, 99, 520-528.
17. Wollina U., Hipler U.C., Knoll B. i inni: Serum matrix metalloproteinase-2 in patients with malignant melanoma. J Cancer Res Clin Oncol 2001, 127, 631-635.
18. Hofmann U.B., Westphal J.R., van Muijen G.N.P. i inni: Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000, 115, 337-344.
19. Ferrier C.M., von Muijen G.N., Ruiter D.J.: Proteases in cutaneous melanoma. Ann Med 1998, 30, 431-442.
20. Tsukifuji R., Tagawa K., Hatamochi A. i inni: Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis. Br J Cancer 1999, 80, 1087-1091.
21. Noe V., Fingleton B., Jacobs K. i inni: Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001, 114, 111-118.
22. Kerkela E., Ala-aho R., Lohi J. i inni: Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Cancer 2001, 84, 659-669.
23. Nakamura H., Fujii Y., Ohuchi E. i inni: Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases. Eur J Biochem 1998, 253, 67-75.
24. Boulay A., Masson R., Chenard M.P. i inni: High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res 2001, 61, 2189-2193.
25. Thewes M., Worret W.I., Engst R. i inni: Stromelysin-3 (ST-3): immunohistochemical characterization of the matrix metalloproteinase (MMP)-11 in benign and malignant skin tumours and other skin disorders. Clin Exp Dermatol 1999, 24, 122-126.
26. Sutinen M., Kainulainen T., Hurskainen T. i inni: Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br J Cancer 1998, 77, 2239-2245.
27. Johansson N., Airola K., Grenman R. i inni: Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997, 151, 499-508.
28. Simon C., Juarez J., Nicolson G.L. i inni: Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase, on urokinase expression and in vitro invasion. Cancer Res 1996, 56, 5369-5374.
29. Hasegawa S., Koshikawa N., Momiyama N. i inni: Matrylysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer 1998, 76, 812-816.
30. Hua J., Muschel R.J.: Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996, 56, 5279-5284.
31. Wojtowicz-Praga S.M., Dickson R.B., Hawkins M.J.: Matrix metalloproteinase inhibitors. Invest New Drugs. 1997, 15, 61-75.
32. Brown P.D.: Clinical studies with matrix metalloproteinase inhibitors. APMIS 1999, 107, 174-180.
33. Chirivi R., Garofalo A., Crimmin M. i inni: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinases. Int J Cancer 1994, 58, 460-464.
34. Bull C., Flynn C., Eberwein D. i inni: Activity of the biphenyl matrix metalloproteinase inhibitor Bay 12-9566 in murine in vivo models. Proc Am Assoc Can Res 1998, 39, 302.
35. Shalinsky D.R., Brekken J., Zou H. i inni: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999, 878, 236-270.
36. Hurwitz H., Humphrey J., Williams K. i inni: A phase I trial of BMS-275291: a novel, non-hydroxamate, sheddase-sparing matrix metalloproteinase inhibitor (MMPI) with no dose-limiting arthritis. Proc Am Soc Clin Oncol 2001, 20, 387.
37. Yoshida H., Kasaoka T., Watanabe T. i inni: Matrix metalloproteinase inhibitor (MMPI) CGS27023A inhibited extravasation of B16-F10 melanoma cells in the experimental metastatic model. Proc Am Assoc Can Res 1999, 40, 705.
38. Golub L.M., Lee H.M., Ryan M.E. i inni: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998, 12, 12-26.
39. Fife R., Sledge G.W.J.: Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med 1995, 125, 407-411.
40. Lokeshwar B.L.: MMP inhibition in prostate cancer. Ann N Y Acad Sci 1999, 878, 271-289.
41. Teronen O., Heikkila P., Konttinen Y.T. i inni: MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999, 878, 453-465.